Cargando…

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623

Detalles Bibliográficos
Autores principales:	Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G., Zhong, Ming, Lee, Tyson T., Houser, Mark T., Frison, Lars, Houghton, John, Little, Dustin J., Peony Yu, Kin-Hung, Neff, Thomas B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Retraction Notice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897481/ https://www.ncbi.nlm.nih.gov/pubmed/35257087 http://dx.doi.org/10.1016/j.ekir.2022.01.1069

Ejemplares similares

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Retraction notice to “Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?” Kidney Int Rep. 2021;6:559–561
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2022)

Corrigendum to “Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity” Kidney Int. Rep. 2021;6:1949-1960.
por: Cody, Ellen M., et al.
Publicado: (2021)

Erratum to “Randomized Trial of Acute Changes in Plasma Phosphate After Phosphorus-Standardized Meals in Peritoneal Dialysis” Kidney Int. Rep. 2021;6:304–312
Publicado: (2021)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Corrigendum to Shi M, Yu S, Ouyang Y, et al. Increased lifetime risk of ESRD in familial IgA nephropathy. Kidney Int Rep. 2021;6:91-100.
Publicado: (2021)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Corrigendum to Ng MS, Malacova E, Hurst C, David MC, Johnson DW, Mallett AJ. “Clinical Outcomes of People With Fabry Disease — ANZDATA Registry Study.” Kidney Int Rep. 2021;6:2481–2485
por: Ng, Monica S., et al.
Publicado: (2022)

Corrigendum to Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis—International Results from PDOPPS. Kidney Int Rep. 2021;6:313-324.
Publicado: (2021)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Corrigendum to “Narita I. Estimating Growth Rate by a Single Measurement of Kidney Volume in ADPKD.” Kidney Int Rep. 2020;5:1383–1384
Publicado: (2021)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

SAT-337 Acute kidney injury in patients with solid organ and haematological malignancies: a single centre experience. Kidney Int Rep. 2019;4:S149
Publicado: (2019)

Ganesh K, Nair RR, Kurian G, et al. Posterior reversible encephalopathy syndrome in kidney disease. Kidney Int Rep. 2018;3:502–507
Publicado: (2018)

Corrigendum to “The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients” [Kidney Int. Rep. 2020 1416–1421]
por: Xu, Xin, et al.
Publicado: (2021)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Corrigendum to Nishank Jain, Milind A. Phadnis, Suzanne L. Hunt, Junqiang Dai, Theresa I. Shireman, Clayton L. Davis, Jawahar L. Mehta, Rafia S. Rasu and S. Susan Hedayati. “Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis”. Kidney Int Rep. 2021;6(9):2381-2391.
Publicado: (2022)

Corrigendum to “Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in Developed Countries.” Kidney Int Rep. 2020;5:263–277
Publicado: (2020)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
por: Hara, Ryujiro, et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
por: Zhang, Li, et al.
Publicado: (2021)

Corrigendum to “Kimura T, Snijder R, Nozaki K. Diagnosis patterns of CKD and anemia in the Japanese population.” Kidney Int. Rep. 2020;5:694–705
Publicado: (2020)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268
Publicado: (2017)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease
por: Zhang, Yanjing, et al.
Publicado: (2023)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637
Publicado: (2018)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

Retracted: Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Corrigendum to “Cataldo E, Cinquantini F, Priola AM, et al. Spontaneous renal artery dissection in Ehler–Danlos syndrome.” Kidney Int Rep. 2019;4:1649–1652
Publicado: (2020)

Erratum to “Perrone RD, Chapman AB, Oberdhan D, et al. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.” Kidney Int. Rep. 2020;5:801–812
Publicado: (2020)

Hollinger A, Wittebole X, François B, et al. Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney Int Rep. 2018;3:1424–1433
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Liu, Chao, et al.
Publicado: (2021)

Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat
por: Tang, Mei, et al.
Publicado: (2021)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9i1up40e7alm8c6co8ig3dhrl